Phenergan
Phenergan Price range: $ 42,00 through $ 136,00
Back to products
PhosLo
PhosLo Price range: $ 48,00 through $ 217,00

Phexin

Price range: $ 70,00 through $ 374,00

Phexin is a highly effective cephalosporin antibiotic designed to treat a wide range of bacterial infections throughout the body. It is commonly used to resolve respiratory tract infections, including bronchitis and pneumonia, as well as painful middle ear infections. The medication is also frequently utilized for managing skin and soft tissue conditions, ensuring a prompt recovery from bacterial inflammation. Additionally, Phexin is a reliable choice for treating urinary tract infections and certain bone-related bacterial issues. By stopping the growth of harmful bacteria, this medication helps restore your health and provides fast relief from bothersome symptoms.

Active substance: cephalexin
SKU: Phexin Category:
Delivery: 5–21 days (depending on the shipping method)
Extra 10% discount with coupon: IT4K6SVM

Each dosage option has its own packaging choices.

Description

Phexin is a prescription antimicrobial formulation containing cephalexin, a first-generation oral cephalosporin antibiotic. It is dispensed in accordance with applicable federal and state regulations in the United States upon presentation of a valid prescription from a licensed healthcare provider.

The active substance in Phexin exhibits bactericidal activity against a broad range of susceptible Gram-positive and Gram-negative bacterial pathogens. It is primarily indicated for treating bacterial infections of the respiratory tract, urinary tract, skin and skin structures, bone, and middle ear, while remaining ineffective against viral syndromes such as influenza or the common cold.

Attribute Details
Active ingredient (INN) Cephalexin
Therapeutic class First-generation Cephalosporin Antibacterial
Route of administration Oral
Primary purpose Treatment of susceptible bacterial infections
Prescription status Prescription only (Rx)
Storage conditions 15°C to 30°C (59°F to 86°F); protect from moisture

Therapeutic Overview

Main uses

Approved clinical indications for cephalexin include respiratory tract infections caused by Streptococcus pneumoniae and Streptococcus pyogenes, otitis media resulting from S. pneumoniae, Haemophilus influenzae, or Staphylococcus aureus, and skin and skin structure infections attributable to staphylococcal or streptococcal organisms. Additionally, it is prescribed for bone infections caused by S. aureus or Proteus mirabilis, as well as genitourinary tract infections, including acute prostatitis, caused by Escherichia coli, Klebsiella pneumoniae, and P. mirabilis. Any therapeutic application outside of these specific bacterial diagnoses established by official labeling constitutes off-label use and requires explicit clinical justification based on microbiological culture and susceptibility testing.

How the drug works

Phexin exerts its therapeutic effect through bactericidal activity via the inhibition of bacterial cell wall synthesis. The active component, cephalexin, binds to specific penicillin-binding proteins (PBPs) located inside the bacterial cell wall membrane. This binding action inhibits the final transpeptidization step of peptidoglycan synthesis, which is critical for maintaining structural integrity of the cell wall in dividing bacteria. Consequently, cell wall synthesis is halted, leading to osmotic instability, cell lysis, and autolytic cell death. Cephalexin is resistant to certain beta-lactamases produced by Gram-positive bacteria, maintaining activity against penicillinase-producing Staphylococcus aureus, though it remains susceptible to hydrolysis by extended-spectrum beta-lactamases (ESBLs) produced by resistant Gram-negative strains.

What happens in the body

Following oral administration, cephalexin is rapidly and almost completely absorbed from the upper gastrointestinal tract. Peak serum concentrations are typically achieved within 1 hour after ingestion under fasting conditions. The drug is acid-stable and exhibits high oral bioavailability. Cephalexin is widely distributed throughout most body tissues and fluids, including synovial, pleural, and pericardial fluid, though penetration into cerebrospinal fluid is negligible even in the presence of inflamed meninges. Serum protein binding is low, ranging from 10% to 15%. The drug undergoes minimal hepatic metabolism and is predominantly excreted unchanged by the kidneys via glomerular filtration and active tubular secretion, with 70% to 90% of an oral dose recovered in urine within 8 hours.

Dosing schedule

Dosing of Phexin must be individualized based on the clinical diagnosis, infection severity, pathogen susceptibility, and the patient’s renal function status. For adult patients, standard oral dosages range from 250 mg to 500 mg administered every 6 hours, or 500 mg administered every 12 hours for uncomplicated cystitis or skin infections. Severe infections may warrant higher dosages up to 4 g daily divided into equal intervals. In pediatric populations, dosage calculations are determined based on body weight, commonly prescribed at 25 mg to 50 mg per kilogram per day in divided doses. To prevent bacterial resistance and treatment failure, the full course of prescribed therapy must be completed regardless of early symptom resolution. Patients with compromised renal clearance require dose adjustments based on serum creatinine or clearance values.

Food and alcohol interactions

Phexin can be taken without regard to food consumption. Administering oral doses alongside meals or snacks may reduce transient gastrointestinal discomfort, such as mild nausea or stomach upset, although food co-administration may slightly delay the time to reach peak plasma concentration without altering overall bioavailability. Ethanol does not exhibit a direct disulfiram-like chemical interaction with cephalexin; however, alcohol consumption is generally discouraged during active antimicrobial therapy as ethanol ingestion can impair immune function, worsen gastrointestinal side effects, and contribute to systemic dehydration.

Special populations

Epidemiological studies and clinical trials have not demonstrated a clear association between cephalexin exposure during pregnancy and major birth defects or adverse maternal-fetal outcomes. Cephalexin passes into human breast milk in low quantities; caution and observation of the nursing infant for adverse effects such as diarrhea or candidiasis are recommended. Elderly patients are more likely to exhibit diminished renal clearance, requiring baseline renal function evaluation and appropriate dosage titrations.

If you skip a dose

If a dose of Phexin is missed, the patient should take the missed dose as soon as it is remembered. However, if the time is close to the next scheduled administration, the missed dose should be omitted, and the regular dosing schedule resumed. Patients must not double the prescribed dose to compensate for a skipped capsule or tablet. Maintaining stable serum concentration levels through consistent interval dosing is essential for eradicating bacterial pathogens.

Storage and expiration

Solid dosage forms of Phexin, such as oral capsules and tablets, should be stored at controlled room temperature between 20°C and 25°C (68°F to 77°F), with excursions permitted between 15°C and 30°C (59°F to 86°F). The medication must be kept in tightly closed containers protected from excessive light, heat, and moisture. Reconstituted oral liquid suspensions require refrigeration between 2°C and 8°C (36°F to 46°F) and must be discarded after 14 days of reconstitution regardless of unused volume.

Safety Profile and Clinical Considerations

Adverse reactions

Adverse reactions to Phexin are predominantly gastrointestinal and dermatological in nature. Common gastrointestinal disturbances include nausea, vomiting, diarrhea, dyspepsia, and abdominal cramps. Pseudomembranous colitis, caused by Clostridioides difficile bacterial overgrowth, represents a serious complication ranging from mild diarrhea to fatal colitis, requiring immediate evaluation if persistent diarrhea occurs during or after therapy. Hypersensitivity manifestations include maculopapular rash, urticaria, pruritus, erythema multiforme, and rare instances of Stevens-Johnson syndrome or anaphylaxis. Transient hematologic alterations–such as eosinophilia, neutropenia, and mild elevations in hepatic transaminases (AST, ALT)–have been documented during prolonged administration.

Important precautions

Prior to initiating Phexin, patients must undergo screening for previous hypersensitivity reactions to cephalosporins, penicillins, or other beta-lactam agents. Cross-sensitivity occurs in approximately 1% to 10% of individuals with penicillin allergy, necessitating caution in patients with a history of severe immediate-type allergic reactions (e.g., anaphylaxis, angioedema) to penicillins. Prescribing Phexin in the absence of a proven or strongly suspected bacterial infection increases the risk of antimicrobial-resistant organisms. Caution is required in patients with pre-existing renal impairment, severe gastrointestinal disease (particularly colitis), or active seizure disorders. Long-term use may result in superinfection with non-susceptible fungal or bacterial species.

Compatibility with other medicines

Concurrent administration of Phexin with other therapeutic agents requires careful pharmacodynamic and pharmacokinetic evaluation. Probenecid competitively inhibits renal tubular secretion of cephalexin, resulting in elevated and prolonged serum drug concentrations. Concomitant therapy with metformin may lead to increased plasma metformin concentrations due to competition for renal organic cation transporters, increasing the risk of metformin-induced metabolic complications. Cephalexin may diminish the immunogenic response of live oral bacterial vaccines, such as the typhoid vaccine (Strain Ty21a); administration of live vaccines should be delayed until completion of antibiotic therapy. Combined use with aminoglycosides or loop diuretics may increase potential nephrotoxic risks, necessitating therapeutic monitoring.

Common questions

How long does it take for Phexin to demonstrate clinical efficacy?

Clinical response typically begins within 24 to 48 hours following the initiation of therapy, manifested by a reduction in fever and improvement of systemic symptoms. However, complete resolution depends on infection severity and tissue site. Treatment must be continued for the full duration prescribed by the physician to ensure complete bacterial clearance.

Can Phexin cause false positive results in diagnostic urine tests?

Yes, cephalexin administration may produce a false-positive reaction for glucose in the urine when using copper reduction tests (such as Benedict’s solution or Fehling’s solution). Enzymatic glucose oxidase tests (such as Clinistix) are not affected. Additionally, a positive direct Coombs’ test may occur during cephalexin therapy.

What steps should be taken if severe diarrhea develops during treatment?

If watery or bloody diarrhea occurs, even weeks after stopping Phexin, patients should contact a healthcare provider immediately. This may indicate Clostridioides difficile-associated diarrhea. Antidiarrheal products containing opioids or diphenoxylate should be avoided, as they may delay toxin clearance and worsen inflammation.

Is dosage modification required for patients with renal impairment?

Yes. Because cephalexin is cleared primarily via renal excretion, patients with reduced glomerular filtration rates (creatinine clearance below 40 mL/min) require dosage reductions or extended administration intervals. Renal function monitoring is recommended for patients with renal insufficiency.

Does Phexin interfere with oral hormonal contraceptives?

While non-rifamycin antibiotics like cephalexin were historically thought to alter intestinal flora and reduce contraceptive steroid reabsorption, current clinical evidence indicates that cephalexin does not significantly decrease plasma concentrations of oral hormonal contraceptives. However, backup non-hormonal contraception may be considered if gastrointestinal disturbances like vomiting or diarrhea occur.

This text is for informational purposes only and does not constitute individual medical advice.

In accordance with FDA requirements.

Additional information
Dosage

500mg

Package

60 caps

,

90 caps

,

120 caps

,

180 caps

,

270 caps

,

360 caps

Ενεργός Ουσία